"Deferoxamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Descriptor ID |
D003676
|
MeSH Number(s) |
D02.092.570.394.265 D02.241.511.372.265
|
Concept/Terms |
Deferoxamine- Deferoxamine
- Desferrioxamine
- Desferioximine
- Deferoxamine B
- Desferrioxamine B
- Deferoximine
- Deferrioxamine B
- Desferroxamine
Desferrioxamine B Mesylate- Desferrioxamine B Mesylate
- Mesylate, Desferrioxamine B
- Deferoxamine Mesilate
- Mesilate, Deferoxamine
- Deferoxamine Mesylate
- Mesylate, Deferoxamine
- Deferoxamine Methanesulfonate
- Methanesulfonate, Deferoxamine
|
Below are MeSH descriptors whose meaning is more general than "Deferoxamine".
Below are MeSH descriptors whose meaning is more specific than "Deferoxamine".
This graph shows the total number of publications written about "Deferoxamine" by people in this website by year, and whether "Deferoxamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2015 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
2018 | 2 | 2 | 4 |
2019 | 1 | 0 | 1 |
2020 | 1 | 0 | 1 |
2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Deferoxamine" by people in Profiles.
-
Transfusion-dependent beta thalassemia in Afghanistan: current evidence amid COVID-19 and future recommendations. Hematology. 2021 Dec; 26(1):432-434.
-
Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021 May 28; 26(11).
-
Hyperferritinemia in patients with COVID-19: An opportunity for iron chelation? Artif Organs. 2021 Feb; 45(2):163-167.
-
Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome? Eur J Clin Pharmacol. 2020 Nov; 76(11):1619-1620.
-
Biocompatibility and toxicity of novel iron chelator Starch-Deferoxamine (S-DFO) compared to zinc oxide nanoparticles to zebrafish embryo: An oxidative stress based apoptosis, physicochemical and neurological study profile. Neurotoxicol Teratol. 2019 Mar - Apr; 72:29-38.
-
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias. Health Qual Life Outcomes. 2018 Nov 19; 16(1):216.
-
Effects of amniotic membrane extract and deferoxamine on angiogenesis in wound healing: an in vivo model. J Wound Care. 2018 Jun 01; 27(Sup6):S26-S32.
-
Ferroptosis-inducing agents compromise in vitro human islet viability and function. Cell Death Dis. 2018 05 22; 9(6):595.
-
Zebrafish larvae as a model to demonstrate secondary iron overload. Eur J Haematol. 2018 Jun; 100(6):536-543.
-
Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice. Mol Med Rep. 2017 Nov; 16(5):6642-6649.